ClinicalTrials.gg
CompletedNCT00866047Updated Mar 22, 2017Results posted

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

A Phase 2 interventional study of brentuximab vedotin in Lymphoma, Large-Cell, Anaplastic and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Completed at 22 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-22.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.

Enrollment
6th of 21
58 · median 44
Started
2009
with 2 others
Phase 2
8 of 21
1 open now
Registered
3rd of 21
by date
Lead sponsor
9 of 21
Seagen Inc.

Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one is the 6th largest by enrollment, is one of 3 that started in 2009, is one of 8 in phase 2, and was the 3rd registered.

Lymphoma, Large-Cell, Anaplastic

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Open to participants now

1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.

03

Conditions studied

  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin

Keywords

  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • monomethyl auristatin E
  • Drug Therapy
  • Immunotherapy
  • Hematologic Diseases
  • Lymphoma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with systemic ALCL who have previously received front line chemotherapy.
  • Documented anaplastic lymphoma kinase (ALK) status.
  • -confirmed CD30-positive disease; tissue from the most recent post diagnostic of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.
  • Fluorodeoxyglucose-avid and of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
  • Received any previous stem cell transplant at least 12 weeks (3 months) prior.
  • At US sites, patients greater than or equal to 12 years of age may be enrolled. At non-US sites, patients must be greater than or equal to 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with brentuximab vedotin.
  • Previously received an transplant.
  • Patients with current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible).
  • Known cerebral/meningeal disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin

    Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

    Drug: brentuximab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate by Independent Review Group

    Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: up to 12 months

Secondary outcomes

  1. Complete Remission Rate by Independent Review Group

    Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: up to 12 months

  2. Duration of Objective Response by Kaplan-Meier Analysis

    Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.

    Time frame: up to approximately 3 years

  3. Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis

    Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.

    Time frame: up to approximately 3 years

  4. Progression-free Survival by Kaplan-Meier Analysis

    Time from start of study treatment to disease progression per independent review group or death due to any cause.

    Time frame: up to approximately 3 years

  5. Overall Survival

    Time from start of study treatment to date of death due to any cause.

    Time frame: up to approximately 7 years

  6. Adverse Events by Severity, Seriousness, and Relationship to Treatment

    Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

    Time frame: up to 12 months

  7. Hematology Laboratory Abnormalities >/= Grade 3

    Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

    Time frame: up to 12 months

  8. Chemistry Laboratory Abnormalities >/= Grade 3

    Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

    Time frame: up to 12 months

  9. Area Under the Curve

    Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  10. Maximum Serum Concentration

    Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  11. Time of Maximum Serum Concentration

    Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

Other outcomes

  1. B Symptom Resolution

    Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

    Time frame: up to 12 months

07

Results

Posted Oct 26, 2011

Participant flow

Enrollment period: Jun 2009 - May 2010

Treatment Period
Participant flow — Treatment Period
MilestoneBrentuximab Vedotin
Started58
Completed10
Not completed48
Withdrew: Progressive disease13
Withdrew: Adverse event16
Withdrew: Physician decision14
Withdrew: Withdrawal by subject5
Follow-up Period
Participant flow — Follow-up Period
MilestoneBrentuximab Vedotin
Started58
Completed53
Not completed5
Withdrew: Lost to follow-up5

Outcome measures

PrimaryObjective Response Rate by Independent Review Group

Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
up to 12 months
Reported as:
Number · percent of participants
Objective Response Rate by Independent Review Group
percent of participantsBrentuximab Vedotin
Objective Response Rate by Independent Review Group86 (74.6 to 93.9)
SecondaryComplete Remission Rate by Independent Review Group

Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
up to 12 months
Reported as:
Number · percent of participants
Complete Remission Rate by Independent Review Group
percent of participantsBrentuximab Vedotin
Complete Remission Rate by Independent Review Group59 (44.9 to 71.4)
SecondaryDuration of Objective Response by Kaplan-Meier Analysis

Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.

Time frame:
up to approximately 3 years
Reported as:
Median · months
Duration of Objective Response by Kaplan-Meier Analysis
monthsBrentuximab Vedotin
Duration of Objective Response by Kaplan-Meier Analysis13.2 (5.7 to 26.3)
SecondaryDuration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis

Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.

Time frame:
up to approximately 3 years
Reported as:
Median · months
Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis
monthsBrentuximab Vedotin
Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis26.3 (13.2 to NA)
SecondaryProgression-free Survival by Kaplan-Meier Analysis

Time from start of study treatment to disease progression per independent review group or death due to any cause.

Time frame:
up to approximately 3 years
Reported as:
Median · months
Progression-free Survival by Kaplan-Meier Analysis
monthsBrentuximab Vedotin
Progression-free Survival by Kaplan-Meier Analysis14.6 (6.9 to 20.6)
SecondaryOverall Survival

Time from start of study treatment to date of death due to any cause.

Time frame:
up to approximately 7 years
Reported as:
Median · months
Overall Survival
monthsBrentuximab Vedotin
Overall SurvivalNA (21.3 to NA)
SecondaryAdverse Events by Severity, Seriousness, and Relationship to Treatment

Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

Time frame:
up to 12 months
Reported as:
Number · participants
Adverse Events by Severity, Seriousness, and Relationship to Treatment
participantsBrentuximab Vedotin
Any TEAE58
TEAE related to study drug53
TEAE with CTCAE severity grade >/=336
Serious adverse event25
Serious adverse event related to study drug11
Discontinued treatment due to adverse event16
SecondaryHematology Laboratory Abnormalities >/= Grade 3

Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

Time frame:
up to 12 months
Reported as:
Number · participants
Hematology Laboratory Abnormalities >/= Grade 3
participantsBrentuximab Vedotin
Any >/= Grade 3 hematology laboratory abnormality17
Leukocytes (low)3
Lymphocytes (low)10
Neutrophils (low)7
Platelets (low)3
SecondaryChemistry Laboratory Abnormalities >/= Grade 3

Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

Time frame:
up to 12 months
Reported as:
Number · participants
Chemistry Laboratory Abnormalities >/= Grade 3
participantsBrentuximab Vedotin
Any >/= Grade 3 chemistry laboratory abnormality13
Aspartate aminotransferase (high)1
Calcium (low)3
Glucose (high)4
Potassium (low)1
Sodium (low)1
Urate (high)3
SecondaryArea Under the Curve

Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Geometric mean · day * microgram/mL
Area Under the Curve
day * microgram/mLBrentuximab Vedotin
Area Under the Curve98 ± 69
Other pre-specifiedB Symptom Resolution

Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

Time frame:
up to 12 months
Reported as:
Number · percent of participants
B Symptom Resolution
percent of participantsBrentuximab Vedotin
B Symptom Resolution82 (56.6 to 96.2)
SecondaryMaximum Serum Concentration

Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Geometric mean · microgram/mL
Maximum Serum Concentration
microgram/mLBrentuximab Vedotin
Maximum Serum Concentration37 ± 20
SecondaryTime of Maximum Serum Concentration

Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Median · days
Time of Maximum Serum Concentration
daysBrentuximab Vedotin
Time of Maximum Serum Concentration0.02 (0.02 to 0.02)

Adverse events

Collected over Adverse events through 30 days after last dose (up to 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin—25/58 (43.1%)58/58 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventBrentuximab Vedotin
Anaplastic large cell lymphoma t- and null-cell types recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/58
Arrhythmia supraventricularCardiac disorders2/58
Septic shockInfections and infestations2/58
Urinary tract infectionInfections and infestations2/58
Pain in extremityMusculoskeletal and connective tissue disorders2/58
AnaemiaBlood and lymphatic system disorders1/58
NeutropeniaBlood and lymphatic system disorders1/58
Acute myocardial infarctionCardiac disorders1/58
Atrial fibrillationCardiac disorders1/58
Atrioventricular block completeCardiac disorders1/58
Most frequent other events
Showing 10 of 66
Most frequent other events
EventBrentuximab Vedotin
Peripheral sensory neuropathyNervous system disorders24/58
NauseaGastrointestinal disorders23/58
FatigueGeneral disorders22/58
PyrexiaGeneral disorders20/58
DiarrhoeaGastrointestinal disorders16/58
RashSkin and subcutaneous tissue disorders14/58
ConstipationGastrointestinal disorders12/58
NeutropeniaBlood and lymphatic system disorders11/58
Upper respiratory tract infectionInfections and infestations11/58
HeadacheNervous system disorders11/58

Baseline characteristics

Age, Customized
Age, Customized(years)Brentuximab Vedotin
Median52.0 (14 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin
Female25
Male33
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American7
White48
More than one race0
Unknown or Not Reported2
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Brentuximab Vedotin
019
138
21
3-50
ALK Status
ALK Status(participants)Brentuximab Vedotin
Positive16
Negative42
08

Study locations

22 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Baylor Sammons Cancer Center / Texas Oncology
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4003, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • B.C Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Institut Paoli Calmettes
    Marseille, 13273, France
  • Hospital Saint Louis
    Paris, 75475, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Christie Hospital NHS
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21. PubMed 22614995 ↗
  • Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3. Erratum In: Blood. 2018 Jul 26;132(4):458-459. doi: 10.1182/blood-2018-05-853192. PubMed 28974506 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Aug 2010 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2009
First posted
Mar 20, 2009
Start
Mar 2009
Primary completionActual
Aug 2010
CompletionActual
Jun 2016
Results first posted
Oct 26, 2011
Last update
Mar 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00866047
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Mar 20, 2009
Start date
Mar 2009
Primary completion
Aug 2010
Completion
Jun 2016
Results posted
Oct 26, 2011
Last update
Mar 22, 2017

Study contacts

Dana Kennedy, PharmD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion